T. Rowe Price Associates
PRVA icon

T. Rowe Price Associates’s Privia Health PRVA Stock Holding History

T. Rowe Price Associates’s Portfolio PRVA Stock Details PRVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.42M Buy
171,902
+36,909
+27% +$855K ﹤0.01% 1623
2026
Q1 		$2.78M Buy
134,993
+24,429
+22% +$551K ﹤0.01% 1684
2025
Q4 		$2.62M Buy
110,564
+9,111
+9% +$222K ﹤0.01% 1638
2025
Q3 		$2.53M Buy
101,453
+9,132
+10% +$197K ﹤0.01% 1633
2025
Q2 		$2.12M Buy
92,321
+13,929
+18% +$323K ﹤0.01% 1609
2025
Q1 		$1.76M Buy
78,392
+4,976
+7% +$116K ﹤0.01% 1664
2024
Q4 		$1.44M Buy
73,416
+9,880
+16% +$196K ﹤0.01% 1799
2024
Q3 		$1.16M Buy
63,536
+1,429
+2% +$27.3K ﹤0.01% 1912
2024
Q2 		$1.08M Buy
62,107
+13,771
+28% +$244K ﹤0.01% 1870
2024
Q1 		$947K Sell
48,336
-672,627
-93% -$14.2M ﹤0.01% 1938
2023
Q4 		$16.6M Sell
720,963
-214,054
-23% -$4.79M ﹤0.01% 993
2023
Q3 		$21.5M Sell
935,017
-21,164
-2% -$538K ﹤0.01% 904
2023
Q2 		$25M Buy
956,181
+868,709
+993% +$22.9M ﹤0.01% 879
2023
Q1 		$2.42M Buy
87,472
+10,957
+14% +$289K ﹤0.01% 1406
2022
Q4 		$1.74M Buy
76,515
+2,077
+3% +$57.8K ﹤0.01% 1525
2022
Q3 		$2.54M Sell
74,438
-2,705,766
-97% -$100M ﹤0.01% 1370
2022
Q2 		$81M Buy
2,780,204
+1,162,270
+72% +$29.5M 0.01% 724
2022
Q1 		$43.2M Buy
1,617,934
+499,816
+45% +$11.8M ﹤0.01% 1014
2021
Q4 		$28.9M Buy
1,118,118
+469,625
+72% +$11.7M ﹤0.01% 1191
2021
Q3 		$15.3M Sell
648,493
-2,158,846
-77% -$75.4M ﹤0.01% 1356
2021
Q2 		$125M Buy
+2,807,339
New +$104M 0.01% 707

Other funds holding PRVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RF
Rubicon Founders Nashville, Tennessee $196M AUM 53.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

T. Rowe Price Associates's PRVA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Privia Health (PRVA) stake by 27% in Q2 2026, buying an estimated $855K and bringing the position to 171,902 shares worth $4.42M. The position accounts for ﹤0.01% of the portfolio, ranked #1623.

T. Rowe Price Associates first reported a position in PRVA in Q2 2021 and has held it in 21 quarters since. The position peaked at $125M in Q2 2021. 301 funds tracked by Wall St. Rank hold PRVA as of Q2 2026.

  • T. Rowe Price Associates held 171,902 shares of Privia Health worth $4.42M as of Q2 2026.
  • T. Rowe Price Associates bought 36,909 Privia Health shares in Q2 2026, an estimated $855K.
  • Privia Health made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1623 holding.
  • T. Rowe Price Associates first reported a position in Privia Health in Q2 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Privia Health position peaked at $125M in Q2 2021.
  • 301 funds tracked by Wall St. Rank held Privia Health as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.